Clinical Trials | August 06, 2025
AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Alopecia areata usually presents as a few small bald patches in the head
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Subscribe To Our Newsletter & Stay Updated
